ArticleMolecular biology reports2026
Rho GTPase-related prognostic signature for esophageal squamous cell carcinoma identifies CTTN as a candidate adverse prognostic marker.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRho GTPases orchestrate actin dynamics and tumor cell motility, but their prognostic relevance in esophageal squamous cell carcinoma (ESCC) remains unclear. We aimed to identify Rho GTPase-related differentially expressed genes (DEGs), build a prognostic model, evaluate important gene expression against clinicopathological features, and examine CTTN function in vitro.
methodsTranscriptomic data from GSE53625 and TCGA-ESCC were used. Rho GTPase-linked DEGs from tumor-normal comparisons entered univariate Cox, LASSO, and multivariable Cox analyses to construct a risk-score model; immune infiltration and a nomogram were also evaluated. For CTTN, 60 paired ESCC tissues were examined by Western blot and immunohistochemistry, and 18 additional pairs by qPCR, with correlations to clinicopathological variables and survival. ESCC cell lines were used to test the effects of CTTN expression on migration, invasion, and proliferation.
resultsWe identified 107 Rho GTPase-related DEGs enriched in actin cytoskeleton-remodeling pathways. Five genes (RHOV, RHOA, PIK3R1, CTTN, ARHGEF37) formed a prognostic signature that separated patients into high-risk and low-risk groups with different outcomes and remained associated with outcome after adjustment for available clinicopathological variables. However, stage and nodal status differed between risk groups, indicating that the signature may partly capture aggressive clinicopathological features. High-risk tumors showed differences in inferred immune-cell abundance, including B-cell, NK-cell, mast-cell, and neutrophil populations. CTTN was consistently upregulated versus normal tissue, especially in advanced-stage and nodal-metastatic disease, and enhanced ESCC cell migration and invasion in vitro.
conclusionsWe developed an exploratory Rho GTPase-based prognostic model for ESCC and identified CTTN as a candidate adverse prognostic marker and functional contributor to ESCC cell migration and invasion. The model, immune-infiltration findings, nomogram, and CTTN-related mechanistic interpretations require further validation in larger prospective cohorts and additional experimental systems.
Indexed as
Identifiers
42364031What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.